This article is more than 5 years old. Information may no longer be current.
Mohs surgery offers greater survival and other top dermatology stories
Click Here to Manage Email Alerts
In the top Healio Dermatology story last week, melanomas of the head and neck treated with Mohs micrographic surgery had a significantly higher overall survival at 5 years after melanoma diagnosis than those treated with wide local excision.
In other top news, researchers say depression and anxiety should be explicitly addressed in updated guidelines on atopic eczema.
Continue reading for the most popular recent stories.
Mohs surgery offers greater survival benefit vs. wide local excision in head and neck melanoma
Invasive melanomas with a Breslow depth of 0.01 mm to 0.74 mm had a statistically significant survival advantage when treated with Mohs micrographic surgery vs. wide local excision. Read more.
Long-term trifarotene safe, effective for facial, truncal acne
Trifarotene cream was safe and well tolerated in the treatment of moderate facial and truncal acne in a multicenter, open-label phase 3 clinical trial. Read more.
Guselkumab shows superior long-term efficacy vs. secukinumab based on PASI 90
A significantly greater proportion of patients with psoriasis receiving guselkumab achieved a 90% reduction or more in the Psoriasis Area and Severity Index at week 48 than those receiving secukinumab. Read more.
Atopic eczema linked with increase in new depression, anxiety
Treated atopic eczema was associated with a 14% increase in the risk for newly diagnosed depression and a 17% increase in a subsequent anxiety diagnosis, regardless of eczema severity. Read more.
Massachusetts General Hospital creates Lancer Endowed Chair of Dermatology
Harold Lancer, MD , announced the Lancer Endowed Chair of Dermatology at Massachusetts General Hospital, which will recognize the talent, accomplishments and work of Richard Rox Anderson, MD, FAAD, director of the Massachusetts General Hospital Wellman Center for Photomedicine, as its first recipient. Read more.